Ignite Creation Date:
2025-12-24 @ 10:52 PM
Ignite Modification Date:
2026-02-10 @ 4:07 PM
Study NCT ID:
NCT02247869
Status:
COMPLETED
Last Update Posted:
2018-02-09
First Post:
2014-03-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
FIL - DDABVD
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None